PepTrackevidence-graded reference
BPC-157
fig.1 — stylized molecular motif
Healing & recovery

BPC-157

Body Protection Compound-157 · stable gastric pentadecapeptide

THE viral non-GLP-1 peptide (Google Trends 8->100, Jan 2023->Apr 2026); 'Wolverine' stack; Huberman/Rogan; face of the 2026 regulatory news.

Evidence
Danimal-only
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
Healing & recovery
Route
Subcutaneous · Intramuscular · Oral
Demand rank
#4 most-searched
01Dosing & Protocol
Typical · reference only
~250-500 mcg/day SC (community); local vs systemic; oral capsules for gut
Titration
Start ~200-250 mcg/day, increase toward 500 mcg if tolerated (no clinical basis)
Reconstitution — illustrative, not a recommendation
10 mg vial + 2 mL BAC = 5000 mcg/mL; 250 mcg = 5 U, 500 mcg = 10 U on U-100. NOTE mg vs mcg = 1000x hazard (human studies dosed in mg).
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal to compound != FDA-approved. WADA S0 prohibited; DoD-prohibited.
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from 503A Category 2 ~22 Apr 2026 (nomination withdrawn)
PCAC review
2026-07-23/24
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows

Animal-heavy; only ~3 tiny uncontrolled human studies (~28 subjects total); no RCTs. 2025 review: 'should not be recommended for clinical use.' Headline efficacy figures are marketing.

04Safety
Contraindications
  • Active/prior cancer (pro-angiogenic; precautionary)
  • Pregnancyhard stop
  • WADA-tested athletes/military
  • Anticoagulant users (uncharacterized - clinician oversight)
Key interactions
  • Anticoagulants - direction uncertain (rat data REDUCED bleeding; do not assert either way)
Serious signals
  • Unknown long-term safety
  • Theoretical angiogenesis/cancer concern
  • Anecdotal anxiety/anhedonia reports (STAT, Feb 2026)
Monitoring
No validated cadence; cancer screening + exclude active malignancy (harm-reduction).
05Related in Healing & recovery
TB-500 (Thymosin beta-4 fragment)
animal-only
grade D →
06Sources
1Current Reviews in Musculoskeletal Medicine 2025
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high (science) / low (dosing)
← All peptides
Healing & recovery

BPC-157

Body Protection Compound-157 · stable gastric pentadecapeptide

THE viral non-GLP-1 peptide (Google Trends 8->100, Jan 2023->Apr 2026); 'Wolverine' stack; Huberman/Rogan; face of the 2026 regulatory news.

Evidence
D
animal-only
Status
Removed from Cat 2 · pending PCAC
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous · Intramuscular · Oral
Community / anecdotal
Demand
#4
most-searched
WADA
Prohibited
tested athletes — avoid
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

~250-500 mcg/day SC (community); local vs systemic; oral capsules for gut

Worked reconstitution example

10 mg vial + 2 mL BAC = 5000 mcg/mL; 250 mcg = 5 U, 500 mcg = 10 U on U-100. NOTE mg vs mcg = 1000x hazard (human studies dosed in mg).

Titration

Start ~200-250 mcg/day, increase toward 500 mcg if tolerated (no clinical basis)

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal to compound != FDA-approved. WADA S0 prohibited; DoD-prohibited.
StatusRemoved from Cat 2 · pending PCAC
503A bulksNot on the bulks list
Category 2 (2026)Removed from 503A Category 2 ~22 Apr 2026 (nomination withdrawn)
PCAC review2026-07-23/24
WADAProhibited (S0)
03

Evidence — the honest read

Danimal-only

Animal-heavy; only ~3 tiny uncontrolled human studies (~28 subjects total); no RCTs. 2025 review: 'should not be recommended for clinical use.' Headline efficacy figures are marketing.

04

Safety

Contraindications
  • Active/prior cancer (pro-angiogenic; precautionary)
  • Pregnancyhard stop
  • WADA-tested athletes/military
  • Anticoagulant users (uncharacterized - clinician oversight)
Key interactions
  • Anticoagulants - direction uncertain (rat data REDUCED bleeding; do not assert either way)
Serious signals
  • Unknown long-term safety
  • Theoretical angiogenesis/cancer concern
  • Anecdotal anxiety/anhedonia reports (STAT, Feb 2026)
Monitoring

No validated cadence; cancer screening + exclude active malignancy (harm-reduction).

06

Sources

01Current Reviews in Musculoskeletal Medicine 2025
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high (science) / low (dosing)